In 2023, Belgium led global antiarrhythmic medicine sales at $18.9M PPP, followed closely by Canada and the Czech Republic. Slovakia and Ireland posted slight increases, while Latvia saw notable growth at 11.49%. In contrast, declines were observed in Canada, Belgium, Austria, and Estonia, with Estonia's sales plummeting by 6.51%. Iceland and Costa Rica experienced moderate growth.
Future trends to watch include potential impacts of healthcare policy reforms, technological advancements in cardiac treatments, and demographic shifts in heart disease prevalence. Geography-specific economic factors and evolving patent landscapes could also influence sales distribution globally.
Top countries in Antiarrhythmic Medicine Sales by Country
| # | 10 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Belgium | 18.9 | 2023 | +1.07% | -0.62% | View data |
| 2 | 2 Canada | 18.1 | 2023 | -2.69% | -2.93% | View data |
| 3 | 3 Czech Republic | 16.7 | 2023 | 0% | +0.61% | View data |
| 4 | 4 Slovakia | 11 | 2023 | 0% | +0.74% | View data |
| 5 | 5 Austria | 8 | 2023 | +1.27% | -0.97% | View data |
| 6 | 6 Ireland | 4 | 2023 | 0% | +0.51% | View data |
| 7 | 7 Latvia | 3.1 | 2023 | 0% | +11.49% | View data |
| 8 | 8 Estonia | 1 | 2023 | 0% | -6.51% | View data |
| 9 | 9 Iceland | 0.8 | 2023 | 0% | +2.71% | View data |
| 10 | 10 Costa Rica | 0.4 | 2023 | 0% | +5.92% | View data |
